NeuroRecovery Technologies

What NeuroRecovery Technologies does

ONWARD Medical N.V. is a Netherlands-based, publicly traded medical device company (Euronext Amsterdam: ONWD) founded in 2014 that develops targeted spinal cord stimulation therapies for individuals with spinal cord injury (SCI) and other neurological conditions. The company's core platform, ARC Therapy, encompasses three technology lines: ARCEX, a non-invasive transcutaneous stimulator that delivers electrical pulses to the cervical spinal cord via skin electrodes; ARCIM, an investigational implantable spinal cord stimulation system intended to restore hemodynamic stability and motor function; and ARCBCI, an investigational brain-computer interface intended to be used with ARCIM to restore walking function after SCI. The lead commercial product, ARCEX, received FDA 510(k) clearance and CE Mark in 2023 and became commercially available for purchase in 2024, indicated for improving hand sensation and strength in patients aged 18-75 with chronic, non-progressive neurological deficit from incomplete SCI (C2-C8 inclusive). The Up-LIFT pivotal trial, the basis for the regulatory clearances, enrolled 65 participants across 14 SCI centers in the US, Europe, and Canada, and demonstrated that 90% of participants improved upper limb strength or function and 87% reported quality-of-life improvement, with results published in Nature Medicine.

The company monetizes ARCEX through hardware sales of the Stimulator and Electrodes to medical centers and rehabilitation facilities, with a quote-based pricing model rather than publicly disclosed list pricing. The go-to-market motion is enterprise field sales into authorized clinical centers, supported by a center locator tool to connect patients with prescribing sites and to enable take-home prescriptions. Customer segments are a hybrid of two primary personas: individuals with SCI and their caregivers (the end users), and trained healthcare professionals and rehabilitation teams at authorized medical centers (the prescribers and administrators). The therapeutic portfolio is also being extended into Parkinson's disease, hemodynamics and blood pressure management, and lower-limb movement applications.

The company has raised approximately €150 million in cumulative funding (a 2014 €1.5M grant, a 2020 €10M Series A, a 2021 €50M Series B, a 2022 €55M Series C, and a 2024 €30M undisclosed round) and listed publicly on Euronext Amsterdam in 2021. ONWARD holds 10 FDA Breakthrough Device Designations and nearly 400 issued or pending patents. Specific headcount is not publicly disclosed; the team is described as comprising scientists, engineers, and physicians. Revenue is not publicly reported, consistent with the company's first full commercial year being 2024.

Name

NeuroRecovery Technologies

Legal name

ONWARD Medical N.V.

Website

https://neurorecoverytechnologies.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

ONWARD Medical is a Netherlands-based, publicly traded medical device company (Euronext: ONWD) developing spinal cord stimulation therapies for spinal cord injury and Parkinson's disease, with the ARCEX non-invasive system commercially available since 2024.

Ownership category

akta.pro rank

Product category

Neurostimulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)

akta.pro secondary industries

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK), Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC), Assistive Technology, Adaptive Equipment & Home Exercise Program Training In-Home (HSABADAN)

Keywords

• Spinal cord stimulation
• Neurostimulation medical devices
• Rehabilitation therapy technology
• Brain computer interface
• Implantable stimulators

Headquarters

HQ city

San Juan Capistrano

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales - ARCEX System: Sale of ARCEX System hardware consisting of Stimulator and Electrodes for non-invasive spinal cord stimulation therapy. Device is sold to medical centers and for home use prescription.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

NeuroRecovery Technologies develops and commercializes spinal cord stimulation systems, including the FDA-cleared non-invasive ARCEX System and the investigational implantable ARCIM System, used to restore motor function and hemodynamic stability in individuals with spinal cord injury. The ARCEX System is sold to medical centers and rehabilitation facilities for in-clinic use and prescribed take-home use, targeting hand sensation and strength improvement in chronic incomplete tetraplegia patients aged 18-75 (C2-C8 inclusive). The company also develops ARCBCI brain-computer interface technology combined with ARCIM, addressing broader applications including lower limb movement and blood pressure management.

Product overview

ONWARD Medical offers a unified platform of neurostimulation therapies under the ARC Therapy brand. The portfolio includes three distinct product lines: ARCEX (external, non-invasive transcutaneous stimulation - FDA cleared and CE marked), ARCIM (implantable stimulation - investigational), and ARCBCI (brain-computer interface - investigational). These products work in conjunction with functional task practice to improve hand sensation, strength, and overall motor function in people with spinal cord injury, with additional applications for Parkinson's disease and autonomic dysfunction.

Differentiator

Problem solved

Functional benefit

Products and services

• ARCEX System Non-invasive transcutaneous spinal cord stimulation system consisting of a Stimulator that delivers electrical pulses to the cervical spinal cord via Electrodes placed on the skin at the back of the neck. Used in conjunction with functional task practice in clinic and take-home exercises to improve hand sensation and strength in individuals aged 18-75 with chronic incomplete spinal cord injury (C2-C8). FDA 510(k) cleared and CE marked; sold to medical centers and prescribed for home use.
• ARCIM System Investigational implantable spinal cord stimulation system designed to restore hemodynamic stability and motor function after spinal cord injury. Not yet available for commercial use; current research published in Nature Medicine covers an implantable system to restore hemodynamic stability after SCI.
• ARCBCI (Brain-Computer Interface) Investigational brain-computer interface technology designed for use in combination with the ARCIM implant to restore motor and autonomic functions, including walking function, after spinal cord injury. Not currently available for commercial use.

Quantifiable outcome

• 90% of participants improved upper limb strength or function; 87% reported quality of life improvement
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• NeuroRestorecoreOthersSwiss spinal cord injury research organization. Listed as a community partner supporting individuals with spinal cord injury.
• Christopher & Dana Reeve FoundationcoreOthersLeading spinal cord injury foundation providing resources and support for individuals with paralysis. Listed as community partner.
• Spinal ResearchminorOthersUK-based spinal cord injury research charity. Listed as community partner supporting the SCI community.
• Wings for LifeminorOthersInternational spinal cord injury research foundation. Listed as community partner.
• Fördergemeinschaft der Querschnittgelähmten (FGQ)minorOthersGerman spinal cord injury self-help organization. Listed as community partner.
• Praxis InstituteminorOthersSpinal cord injury research and training institute. Listed as community partner.
• North American Spinal Cord Injury Consortium (NASCIC)minorOthersNorth American consortium supporting spinal cord injury organizations and individuals. Listed as community partner.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Boston Scientific: Operates the Precision Spectra and WaveWriter SCS portfolios alongside DBS and deep-brain stimulation; a major SCS incumbent whose adjacencies overlap with ONWARD's spinal cord stimulation focus.
• Medtronic: Largest neuromodulation incumbent with Vanta and Intellis spinal cord stimulation systems plus broad DBS and sacral nerve stimulation franchises; has the commercial scale and R&D resources to enter SCI rehabilitation.
• Abbott: Markets the Proclaim family of SCS and DRG stimulation systems and has an active neuromodulation pipeline; competes broadly in the same device category as ONWARD.

Emerging players

• SpineX: Early-stage company developing transcutaneous spinal cord stimulation for SCI and cerebral palsy; directly comparable emerging peer in non-invasive SCI neurostimulation.
• Blackrock Neurotech: Develops implantable brain-computer interface systems aimed at restoring motor function and communication for people with paralysis; overlaps with ONWARD's ARCBCI motor-restoration goal.
• Neuralink: High-profile BCI developer targeting motor restoration and communication in paralysis; long-term competitor in the BCI-for-SCI space that ONWARD's ARCBCI is positioned to address.
• Synchron: Brain-computer interface company developing an implantable endovascular neural interface for paralysis; relevant BCI-for-paralysis peer to ONWARD's ARCBCI program.
• Saluda Medical: Developer of closed-loop, evoked-compound-action-potential-driven spinal cord stimulation systems; an emerging SCS technology player that competes for next-generation neurostimulation share.
• Helius Medical Technologies: Commercializes non-invasive neurostimulation platforms (e.g., Portable Neuromodulation Stimulator) targeting neurological symptoms including balance and gait; comparable emerging non-invasive neurostimulation peer.

Direct peers

• .NeuroRestore (formerly GTX Medical): Swiss spinal cord injury research organization and listed community partner of ONWARD; develops epidural and transcutaneous spinal cord stimulation technologies for SCI motor recovery, directly overlapping ONWARD's ARC Therapy platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/nrt_inc
• LinkedInlinkedin.com/company/neurorecovery-technologies-inc.

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroRecovery Technologies